Similar to our observations, trastuzumab (anti-HER2 antibody) was shown to upregulate PD-L1 level in HER2-overexpressing human breast cancer cells by stimulating human peripheral blood mononuclear cells to release IFNγ.21 This evidence concerns the gene IFNG and breast carcinoma.